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Pancreatic cancer is one of the most aggressive hu­
man cancers. Advanced pancreatic cancer is associa­
ted with a poor prognosis although surgical resection or 
radiotherapy is potentially curative for localized disease. 
5­year survival rates for patients with pancreatic cancer 
are less than 5% and the median survival time is less 
than 6 months [1]. Multimodality treatments, including 
surgery, chemotherapy, and post­operative radiation 
therapy, have resulted in only an incremental increase in 
survival. Novel therapeutic approaches that can change 
the course of the disease are urgently needed.
Histone deacetylase (HDAC) inhibitors seem to be 
a new class of anticancer agents. In numerous cancers, 
alterations in histone acetyl transferase (HAT) or HDAC 
activity occur and overactivation of the HDAC enzymes re­
sults in histone hypoacetylation. By altering the acetylation 
status of an array of substrates, inclu ding histones, trans­
cription factors, and chaperone proteins, HDAC inhibitors 
have been shown to induce growth arrest, differentiation, 
and/or apoptosis of proliferating cancer cells [2–4]. 
Trichostatin A (TSA), the most common HDAC inhibitor, 
has been shown to have antitumor effects on pancreatic 
cancer, either alone or in combination with gemcitabine. 
These effects may result from alteration of the transcrip­
tional profile where genes such as p21, which promotes 
cell cycle arrest, are up­regulated, whereas genes, such 
as 5’­nucleotidase UMPH (uridine monophosphate phos­
phohydrolase) type α gene, which prevents the formation 
of the active forms of gemcitabine, are down­regulated 
[5–9]. However, until now, therapy with HDAC inhibi­
tors has been based on classic protein­coding tumor­
suppressor genes, and only a few genes were found to 
be affected. Thus, to explore additional mechanisms of 
HDAC inhibitors influence, changes of the microRNAs 
(miRNAs) expression profile in pancreatic cancer cell line 
BxPC­3 following treatment with TSA were examined.
miRNAs are ~22 nucleotide (nt) noncoding RNAs 
that regulate gene expression by translational repression 
when partially complementary sequences are present in 
the 3’untranslated regions (3’UTR) of the target mRNAs 
or by directing mRNA degradation. miRNAs are ex­
pressed in a tissue­specific manner and are considered 
to play important roles in cell proliferation, apoptosis, and 
differentiation [10–13]. Moreover, altered expression of 
miRNAs has been shown to be associated with many 
human diseases including cancer. Aberrant miRNAs 
expression in pancreatic cancer contributes to tumor 
cell proliferation and survival [14–17]. In this study, we 
examined whether the HDAC inhibitor TSA can affect 
cell growth, apoptosis and alter expression of miRNAs 
in pancreatic cancer cell line BxPC­3.
MATERIALS AND METHODS
Materials. The human BxPC­3 cell line was ob­
tained from the American Type Culture Collection 
(Manassas, VA). TSA was purchased from Sigma, USA, 
dissolved in absolute ethanol and stored at –20 °С.
Cell culture. BxPC­3 cells were cultured in RPMI 
1640 supplemented with 20 mM glutamine, 10% fetal 
bovine serum, 100 IU/mL penicillin, and 100 µg/mL 
streptomycin, and were incubated at 37 °C in a humidi­
fied incubator with 5% CO2.
Cell viability assay. Cell viability was assessed by 
the MTT­based cytotoxicity assay. BxPC­3 cells were 
trypsinized and seeded in 96­well plates at a density of 
2 × 103 cells/well and cultured overnight. Cells were then 
treated with different concentrations of TSA (0.1, 0.5, 1.0, 
2.0 µmol/L) or control (0.1% ethanol) for 24–72 h. At the 
completion of incubation, media was replaced with fresh 
complete media (100 µl). 4 h before the end of the incuba­
tion period, 20 µl of PBS contai ning MTT (5 mg/mL) were 
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added to each well. Following this, the plates were centri­
fuged at 200 × g for 5 min and media was removed. The 
precipitate was then resuspended in 150 µl of DMSO. The 
absorbance was measured on a plate reader at 570 nm. 
Each experiment was performed in triplicates.
Cell cycle analysis. For cell cycle assay, BxPC­3 
cells (at least 1 × 106 cells) treated with TSA at concen­
tration of 1.0 µmol/L or 0.1% ethanol for 24 h were har­
vested and washed with PBS, and fixed in 90% ethanol 
for 1 h at – 20 °C. Prior to analysis, the cells were washed 
and resuspended in PBS, and incubated with 1 g/L of 
RNase I and 20 g/L of propidium iodide (PI) at 37 °C for 
30 min. Fluorescence was quantified on a flow cytometry, 
and the percentage of cells in each phase was calculated 
using ModFit software (BD Biosciences).
Apoptosis assessment by Annexin V staining. An­
nexin V­FITC kit (Jingmei Biotech) was used to measure 
the percentage of apoptotic cells induced by 1.0 µmol/L 
TSA. After 24 h incubation, cells were harvested and 
washed with PBS at 4 °C and then resuspended in 100 µl 
of the staining solution containing 5 µl Annexin V­FITC 
and 10 µl PI. After incubation at room temperature for 
15 min, stained cells were analyzed by flow cytometry.
miRNA microarray analysis. miRNA expression 
profiling was carried out according to the manufacturer’s 
introduction. In brief, miRNA was isolated from untreated 
cells and cells treated with 1.0 µmol/L TSA for 6 h using 
mirVana miRNA isolation kit according to manufacturer’s 
instructions (Ambion). Purified miRNA was labeled with 
Cy3 and then hybridized to the miRNA microarray chip 
containing 576 human miRNA probes. Each probe on the 
microarray slide is printed in duplicate with positive and 
negative controls. Following hybridization, the slides were 
washed, dried and scaned on a LuxScan 10K/A Scanner 
(CapitalBio Corp., China). Database calculations were 
done and expression maps were generated with Signifi­
cance Analysis of Microarrays (SAM) for Excel.
Northern blotting. To verify the reliability of the 
expression changes detected by the profiling analysis 
using the microRNA array, Northern blotting with the same 
RNA samples that had been used for the microarray was 
performed for the elective number of microRNAs. RNA 
samples (20 µg each) were separated on 15% denaturing 
polyacrylamide gel and then electroblotted onto a Zeta­
Probe G1 Blotting Membrane (Bio­Rad). Following trans­
fer, the membrane was dried and UV cross­linked. The 
probes were prepared using the StatFne Oligonucleo tide 
Labeling System (Integrated DNA Technologies) accor­
ding to the manufacturer’s protocol. The blots were hy­
bridized at 50 °C in a buffer containing 5 × SSC, 20 mmol/L 
Na2PO4 (pH 7.2) 7% SDS, 1 × SSC/1% SDS buffer for 
16 h. The probe sequences are as follows: miR­200c 
5’­ACATCGTTACCAGACAGTGTTA­3’, miR­21 5’­TCAA­
CATCAGTCTGATAAGCTA­3’. U6 RNA (5’­GCAGGGGC­
CATGCTAATCTTCTCTGTATCG­3’) was used to normalize.
Statistical analysis. SPSS statistical software (ver­
sion 12.0) was used for analysis. Statistical significance 
was determined using the analysis of variance (ANOVA). 
Data are expressed as mean ± standard deviation (SD). 
A P­value < 0.05 was considered statistically significant.
RESULTS
TSA inhibited pancreatic cancer cell viabi lity. To 
examine the antiproliferative effect of TSA on BxPC­3 
pancreatic cancer cells, we treated the cells with TSA 
at concentrations from 0.1 µmol/L to 2.0 µmol/L for 
24–72 h. As shown in Fig.1, TSA significantly inhibited 
the viability of BxPC­3 cells significantly in a time­ and 
dose­dependent manner. Inhibition of cell viability was 
observed even at the lowest concentration. Exposure 
to TSA for 72 h at the concentration of 2.0 µmol/L 
caused a 72.6% (± 0.2) decrease of cell viability.
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Fig. 1. The cell viability curve of pancreatic cancer cells BxPC­3 
treated with TSA. BxPC­3 cells were treated with TSA at various con­
centrations for 24–72 h and cell viability was measured with MTT. TSA 
inhibited cell viability in a dose­ or time­dependent manner, n = 3
Induction of cell cycle arrest and apoptosis by 
TSA. Cell cycle analysis showed that 24 h after the 
treatment of BxPC­3 cells with 1.0 µmol/L TSA, 19% 
increase of cells in the G0/G1 phase (P < 0.05, Table 1) 
was observed, indicating arrest of the cells at the G0/G1 
transition. The flow cytometry analysis with Annexin 
V­FITC and PI staining showed that TSA induced the 
apoptosis of BxPC­3 cells. The apoptosis rate was in­
creased significantly up to 25% in BxPC­3 cells treated 
with 1.0 µmol/L TSA vs 5% in the control cells (Fig. 2). 
Table 1. Effect of TSA (1.0 µmol/L) on the cell cycle distribution of 
BxPC-3 cells (%, mean ± SD)
Groups Cell cycle distributionG0/G1 S G2/M
Blank 42.5 ± 2.2 33.2 ± 1.9 24.3 ± 3.1
Ethanol 47.3 ± 3.4 27.4 ± 2.3 25.3 ± 1.3
TSA 61.8 ± 2.5* 24.9 ± 4.2 13.3 ± 1.8
Notes: Experiment was carried out in triplicates (106 cells per each sample). 
Mean ± SD, *P < 0.05 vs Blank or Ethanol.
Fig. 2. TSA induced cell apoptosis in pancreatic cancer cells 
BxPC­3. 24 h after treatment, cell apoptosis was detected using 
FCM. a, Mock cells; b, Cells treated with ethanol control; c, Cells 
treated with 1.0 µmol/L TSA. AnnexinV­FITC and PI staining showed 
that TSA caused an apoptosis effect. The percentage rate of apop­
tosis was significantly increased to 25% in BxPC­3 cells treated with 
1.0 µmol/L TSA, compared with 5% in control (P < 0.001)
Alteration of miRNAs levels following treatment 
with TSA. To assess the response of miRNAs to TSA, 
the expression profile of miRNAs from the pancreatic 
cancer cell line BxPC­3 treated for 6 h with 1.0 µmol/L 
TSA was determined by miRNA microarray analysis. Hi­
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erarchical clusterings of miRNAs expression in the TSA­
treated and untreated cells are shown in Fig. 3. Upon 
TSA treatment, the expression levels of BxPC­3 miRNAs 
were altered: 24 miRNAs were down­regulated and 
5 miRNAs were up­regulated. To validate these miRNA 
microarray results, Northern analysis for several of the 
most abundantly expressed miRNAs was performed. As 
could be seen from Fig. 4, Northern blots showed the 
up­regulation of miR­200c and the down­regulation of 
miR­21 after TSA treatment of the cells confirming the 
miRNA microarray result for these miRNAs.
Fig. 3. Hierarchically clustered (average linkage) heat map of 
TSA­induced changes in miRNA expression in BxPC­3 cells. 
Lane 1–2, untreated; Lane 3–4, TSA­treated. Red, significantly 
higher in treated cells; green, significantly lower in treated cells 
in comparison with untreated cells
Fig. 4. Northern blots validating array results for miR­200c, 
which is up­regulated, and miR­21, which is down­regulated. 
Blots were normalized with a probe for U6. Lane 1–2, untreated; 
Lane 3–4, TSA­treated
DISCUSSION
Accumulating evidence is showing that the HADCs 
play an important role in the carcinogenesis, and HADCIs 
emerge as a new class of potential anticancer drugs, 
because they can induce the growth inhibition, cell cycle 
arrest and apoptosis in cancer cell as well as increase the 
sensitivity of cancer cell to chemotherapy and ionizing 
radiation. The mechanism of HDACIs action, however, 
can vary from cell line to cell line [18–21]. Mechanistic 
understanding of the antitumor programs initiated by 
HDACIs through the transcriptional regulation of key cel­
lular genes, at both transcript and protein levels, remains 
a challenging problem.
TSA has been reported to have growth inhibition 
effect on pancreatic cancer cells, but the exact mecha­
nisms have not been well studied. The present studies 
have shown that TSA has a dramatic effect on the vi­
ability and apoptosis of pancreatic cancer cells.
Several investigators have reported that epigenetic 
mechanisms such as DNA methylation and histone modi­
fications, can affect the expression of miRNAs [22–25]. 
LAQ824, one of HDACIs, can lead to a rapid change in 
miRNA expression profile in breast cancer cell line SKBr3 
[26]. In particular, miR­127, which can down­regulate 
BCL6, was found to be remarkably up­regulated in cancer 
cell lines after the treatment with 5­Aza­CdR, a potent DNA 
methylation inhibitor, and 4­phenylbutyric acid, a histone 
deacetylase inhibitor [27]. It was demonstrates that epige­
netic drugs may exert their antitumor effects on two fronts: 
they not only turn on the tumor­suppressor genes that 
were aberrantly silenced epigenetically, but they also turn 
on tumor­suppressor miRNAs that down­regulate target 
oncogenic mRNAs. In contrast to these investigations, 
Diederichs et al. [28] did not find significant alterations in 
miRNA expression patterns following either DNA demethy­
lation or HDAC inhibitor treatment in A549 lung cancer cells. 
In our experiment, using miRNA microarray analysis, 
we found that 6 h treatment of cells with TSA induced 
altered expression of miRNAs: 29 miRNAs including 
miR­21, ­181b, ­181d, ­221, ­126, ­375, let­7a, and let­7c 
were significantly down­regulated and miR­200c, ­100, 
­34a, ­146a, and ­146b were up­regulated. By Northern 
blot analysis we showed that miR­200c was up­regulated 
and miR­21 was down­regulated following TSA treatment. 
miR­21 is found to be antiapoptotic, and it is up­regulated 
in hepatocellular cancer [29], breast cancer [30], and 
glioblastomas [31]. Considering the expression changes 
of miR­21 associated with TSA, we postulate that the post­
transcriptional effects of HDACIs may play an important 
role in mediating their anticancer activity. Park et al [32] 
have demonstrated that increasing miR­200 levels may 
induce mesenchymal­to­epithelial transition and reduce 
the aggressiveness in human cancer cell lines.
In conclusion, the results of this study show that 
TSA is a potent HDACI that is effective in inhibiting 
the growth of pancreatic cancer cells in vitro. miRNA 
expression profiling of pancreatic cancer cell line 
treated with TSA should provide valuable information 
for further research on the therapeutic potential of 
histone modifications and miRNAs.
ACKNOWLEDgEMENTS 
This project was supported by the Natural Scien­
ce Foundation of Guangdong Province, China 
(No. 04009381, No. 8151008901000139).
REFERENCES
1. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancrea tic 
cancer: basic and clinical aspect. Gastroenterology 2005; 128: 
1606–25.
268 Experimental Oncology 30, 265–268, 2008 (December)
2. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human 
disease and prospects for epigenetic therapy. Nature 2004; 429: 457–63.
3. Shankar S, Srivastava RK. Histone deacetylase inhibitors: 
mechanisms and clinical significance in cancer: HDAC inhibitor-
induced apoptosis. Adv Exp Med Biol 2008; 615: 261–98.
4. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase 
inhibitors: multifunctional anticancer agents. Cancer Treat Rev 
2006; 32: 157–65.
5. Gahr S, Ocker M, Ganslmayer M, et al. The combination 
of the histone-deacetylase inhibitor trichostatin A and gemcitabine 
induces inhibition of proliferation and increased apoptosis in pan-
creatic carcinoma cells. Int J Oncol 2007; 31: 567–76.
6. Donadelli M, Costanzo C, Beghelli S, et al. Synergistic inhibi-
tion of pancreatic adenocarcinoma cell growth by trichostatin A and 
gemcitabine. Biochim Biophys Acta 2007; 1773: 1095–106.
7. Piacentini P, Donadelli M, Costanzo C, et al. Trichostatin A 
enhances the response of chemotherapeutic agents in inhibi ting pan-
creatic cancer cell proliferation. Virchows Arch 2006; 448: 797–804.
8. Moore PS, Barbi S, Donadelli M, et al. Gene expression 
profiling after treatment with the histone deacetylase inhibitor 
trichostatin A reveals altered expression of both pro- and anti-
apoptotic genes in pancreatic adenocarcinoma cells. Biochim 
Biophys Acta 2004; 1693: 167–76. 
9. Donadelli M, Costanzo C, Faggioli L, et al. Trichostatin A, an 
inhibitor of histone deacetylases, strongly suppresses growth of pan-
creatic adenocarcinoma cells. Mol Carcinog 2003; 38: 59–69.
10. Calin GA, Croce CM. MicroRNA signatures in human 
cancers. Nat Rev Cancer 2006; 6: 857–66.
11. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modu-
late hematopoietic lineage differentiation. Science 2004; 303: 83–6.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell 2004; 116: 281–97.
13. Ambros V. The functions of animal microRNAs. Nature 
2004; 431: 350–5.
14. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA 
expression patterns to differentiate pancreatic adenocarcinoma from 
normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901–8.
15. Szafranska AE, Davison TS, John J, et al. MicroRNA ex-
pression alterations are linked to tumorigenesis and non-neoplastic 
processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 
26: 4442–52.
16. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identi-
fies microRNA signature in pancreatic cancer. Int J Cancer 2007; 
120: 1046–54.
17. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expres-
sion profiling of microRNA precursors in human cancer cell lines. 
Nucleic Acids Res 2005; 33: 5394–403.
18. Habold C, Poehlmann A, Bajbouj K, et al. Trichostatin A 
causes p53 to switch oxidative-damaged colorectal cancer cells from 
cell cycle arrest into apoptosis. J Cell Mol Med 2008; 12: 607–21.
19. Li GC, Zhang X, Pan TJ, et al. Histone deacetylase inhibitor 
trichostatin A inhibits the growth of bladder cancer cells through 
induction of p21WAF1 and G1 cell cycle arrest. Int J Urol 2006; 
13: 581–6.
20. Strait KA, Dabbas B, Hammond EH, et al. Cell cycle 
blockade and differentiation of ovarian cancer cells by the histone 
deacetylase inhibitor trichostatin A are associated with changed in 
p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181–90.
21. El-Khoury V, Breuzard G, Fourré N, Dufer J. The histone 
deacetylase inhibitor trichostatin A downregulates human MDR1 
(ABCB1) gene expression by a transcription-dependent mecha-
nism in a drug-resistant small cell lung carcinoma cell line model. 
Br J Cancer 2007; 97: 562–73.
22. Yang N, Coukos G, Zhang L. MicroRNA epigenetic altera-
tions in human cancer: one step forward in diagnosis and treatment. 
Int J Cancer 2008; 122: 963–8.
23. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr 
Res 2007; 61: 24R–29R.
24. Saito Y, Jones PA. Epigenetic activation of tumor suppressor 
microRNAs in human cancer cells. Cell Cycle 2006; 5: 2220–2.
25. Yu WP, Scott SA, Dong WF. Induction of ID1 expression 
and apoptosis by the histone deacetylase inhibitor (trichostatin A) in 
human acute myeloid leukaemic cells. Cell Prolif 2008; 41: 86–97.
26. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration 
of microRNA levels by histone deacetylase inhibition. Cancer Res 
2006; 66: 1277–81.
27. Saito Y, Liang G, Egger G, et al. Specific activa-
tion of microRNA-127 with downregulation of the pro-
to-oncogene BCL6 by chromatin-modifying drugs 
in human cancer cells. Cancer Cell 2006; 9: 435–43.
28. Diederichs S, Haber DA. Sequence variations of microRNAs 
in human cancer: alterations in predicted secondary structure do 
not affect processing. Cancer Res 2006; 66: 6097–104.
29. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 
regulates expression of the PTEN tumor suppressor gene in human 
hepatocellular cancer. Gastroenterology 2007; 133: 647–58.
30. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor 
growth. Oncogene 2007; 26: 2799–803.
31. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is 
an antiapoptotic factor in human glioblastoma cells. Cancer Res 
2005; 65: 6029–33.
32. Park SM, Gaur AB, Lengyel E, et al. The miR-200 fami ly 
determines the epithelial phenotype of cancer cells by targe ting the 
E-cadherin repressors and ZEB2. Genes Dev 2008; 22: 894–907.
ВЛИЯНИЕ ТРИХОСТАТИНА А НА ВЫЖИВАЕМОСТЬ КЛЕТОК РАКА 
ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ BxPC-3 И ЭКСПРЕССИЮ микроРНК
Цель: изучить влияние трихостатина A (TSA) на ингибирование пролиферации клеток и индукцию апоптоза в клеточной линии 
рака поджелудочной железы человека. Методы: для оценки жизнеспособности клеток после их обработки TSA применяли 
основанный на MTT цитотоксический тест. Распределение клеток по фазам клеточного цикла и процент апоптических клеток 
определяли с помощью проточной цитофлуориметрии. Экспрессию микроРНК изучали с использованием микроРНК-чипа. 
Экспрессия miR-200c и miR-21 исследована с помощью Нозерн-блот анализа. Результаты: TSA значительно ингибировал 
пролиферацию клеток линии рака поджелудочной железы человека BxPC-3, и этот процесс зависел от времени инкубации 
и концентрации препарата. Клетки BxPC-3, обработанные TSA, были остановлены в G0/G1-фазе клеточного цикла, увели-
чивалось количество апоптотических клеток, что сопровождалось изменением экспрессии микроРНК. Выводы: полученные 
результаты позволяют предположить, что TSA может активировать экспрессию микроРНК, которые в свою очередь вы-
ступают онкосупрессорами опухоли в клетках линии рака поджелудочной железы BxPC-3.
Ключевые слова: рак поджелудочной железы, трихостатин A, микроРНК.
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